CD8A and neoplasm: However, recent studies have shown that JHU083, a broad-spectrum inhibitor of Gln metabolism, effectively kills tumor cells while activating the anti-tumor effects of CD8+ T cells, thereby significantly enhancing the efficacy of anti-PD-1 immunotherapy (15).